Development of an ELISA assay for EV quantification to assist the large-scale EV manufacture

Xin Zhou, Wenli Wang, Lei Zhang, Shiyi Yang, Xincheng Peng, Xin Zhang, Jinxiu Zhao, Xinjun He, Ke XubioRxiv 2024 · DOI

TL;DR

This paper introduces a new ELISA-based assay for accurately quantifying extracellular vesicles (EVs), a crucial step in large-scale EV manufacturing. This assay overcomes the limitations of existing methods like NTA, which struggle with impurities in crude samples, paving the way for better quality control and process optimization in EV production.

What Problem Does This Paper Address?

The production of extracellular vesicles (EVs) for therapeutic and diagnostic applications is a rapidly growing field. However, scaling up EV manufacturing presents significant challenges, particularly in ensuring consistent quality, safety, and yield. Accurate quantification of EVs is paramount at every stage of production, from monitoring cell culture conditions (upstream) to controlling purification efficiency (downstream).

The current gold standard for EV quantification, Nanoparticle Tracking Analysis (NTA), faces a major hurdle: it's easily confounded by the presence of non-EV particles and contaminants commonly found in crude samples like cell culture media. This interference leads to inaccurate measurements, hindering effective process development and in-process control. Other available methods also have their own limitations, such as high cost or low throughput, making them less suitable for industrial-scale manufacturing. This paper aims to fill this gap by developing a highly specific and accurate ELISA assay that can reliably quantify EVs even in complex, crude samples.

Methods

The core of this paper is the development and validation of a novel Vesicure human EV (CLIA) ELISA detection kit. The assay employs a sandwich ELISA format, leveraging specific antibody-antigen interactions for EV detection.

Here's a breakdown of the key methodological aspects:

  • Capture Antibody: The assay utilizes a 96-well plate coated with an anti-CD81 antibody to capture EVs from the sample. CD81 is a well-established EV surface marker.
  • Detection Antibodies: Biotinylated anti-CD63 and anti-CD9 antibodies are used as detection antibodies. These target other common EV surface markers, enhancing the specificity of the assay.
  • Signal Amplification: HRP-Streptavidin is added, which binds to the biotinylated detection antibodies. This complex then catalyzes a chemiluminescent substrate, generating a light signal proportional to the amount of EVs present.
  • Standardization: A critical aspect is the use of highly purified EVs derived from HEK293 or MSC cells as the standard sample. This ensures the accuracy of the calibration curve and subsequent measurements.
  • Purification of Standards: To obtain these pure EV standards, the researchers employed Density Gradient Ultracentrifugation (DGUC). This method separates EVs based on their density, effectively removing protein aggregates and other contaminants.
  • Validation Techniques: The assay's performance was rigorously validated using several techniques:
  • Transmission Electron Microscopy (TEM): Used for visualizing the morphology of purified EVs and assessing sample purity.
  • Size Exclusion High-Performance Liquid Chromatography (SE-HPLC): Employed to analyze the purity of EV samples by separating molecules based on size.
  • Nano-Tracking Analysis (NTA): Used for comparison and validation, though its limitations in crude samples are highlighted.

Datasets

The paper does not explicitly mention the use of large, pre-existing datasets for training. Instead, it focuses on the development and validation of a new assay using experimental samples.

  • EV Samples: Purified EVs from HEK293 and MSC cell lines were used as standard samples.
  • Crude Samples: Harvested cell culture media (CM) from both HEK293 and MSC cell lines were used as representative crude samples for testing the assay's performance in complex matrices.
  • Non-EV Samples: Various non-EV samples, including Human IgG, Human CD81, Human CD9, and Human CD63, were used to assess the specificity of the ELISA assay.

Key Insights and Ideas

  • Specificity is Key for Crude Samples: The paper strongly emphasizes that for accurate EV quantification in complex biological fluids (like cell culture media), an assay must be highly specific to avoid interference from non-EV particles. The use of multiple EV surface markers (CD81, CD63, CD9) in their ELISA design is a key strategy to achieve this.
  • The Problem with NTA in Manufacturing: The research clearly illustrates why NTA, while useful in academic settings, is problematic for large-scale EV manufacturing. Its susceptibility to contaminants directly impacts the reliability of upstream and downstream process monitoring.
  • The Importance of Pure Standards: The accuracy of any quantitative assay hinges on the quality of its standards. The paper highlights the necessity of using ultra-pure EV standards, obtained through methods like DGUC, to ensure reliable calibration.
  • ELISA as a Viable Alternative: The development of this ELISA kit demonstrates that a well-designed immunoassay can effectively overcome the limitations of NTA, offering a more robust solution for EV quantification in industrial settings.
  • Bridging the Gap from Lab to Industry: The assay is specifically designed to support both research and development (method development) and in-process control in large-scale EV manufacturing, addressing a critical need in the field.

Key Results

  • Detection Range: The assay boasts a broad detection range of 4.1E7 to 3E10 EVs/mL.
  • Sensitivity: The Limit of Detection (LOD) was determined to be 1.04E7 EVs/mL, and the Limit of Quantification (LOQ) was 3.21E7 EVs/mL.
  • Specificity: The assay showed good specificity, with non-EV samples testing below the detection limit.
  • Accuracy: Dilution linearity experiments showed minimal matrix effects, and recovery rates of spiked EV samples in cell culture media ranged from 75%-125%, indicating good accuracy.
  • Precision: The coefficient of variation (CV) for replicate measurements was less than 15%, demonstrating good assay precision.
  • Performance in Crude Samples: The ELISA kit was successfully applied to harvested cell culture fluid (MSC CM) and demonstrated reliable quantification, showing consistent trends with NTA and TEM when comparing purified samples.
  • Downstream Process Monitoring: The assay was also applied to monitor EV concentrations during downstream purification steps, showing high recovery rates (over 85%) for various intermediate products.

Limitations and Future Work

  • Standard Sample Purity: While DGUC is effective, the paper acknowledges that achieving absolute purity can be challenging, and the presence of residual impurities in the standard sample could theoretically impact accuracy. However, their purity assays (TEM, SE-HPLC) suggest the standards are highly appropriate.
  • Comparison with NTA: The paper consistently points out the limitations of NTA in crude samples. While they show that their ELISA results align better with TEM for purified samples, a direct, comprehensive comparison of their ELISA against NTA on a wider range of crude samples with varying impurity profiles could further strengthen the argument.
  • Broader EV Types: The current kit is described as a "Vesicure total human EVs quantitation ELISA (CLIA) kit." Future work could explore the development of kits specific for different EV subtypes or from various species, if needed for specific applications.
  • Clinical Applications: While the paper states the kit holds "great potential for a variety of industrial, research, and clinical applications," further validation in clinical samples would be a logical next step to explore its diagnostic or prognostic utility.

Summary updated

Abstract

Abstract Accurate EV quantitation is essential for ensuring quality, consistency, and safety during large-scale extracellular vesicle (EV) manufacturing. In the upstream phase, EV quantitation allows for the monitoring of cell culture conditions that impact EV yield and quality, while in the downstream phase, it helps to control the efficiency and purity of EV purification. Nanoparticle Tracking Analysis is the most commonly used method for EV quantification, while it faces significant limitations due to interference from nanosize contaminants like protein aggregates, especially in crude samples (e.g. cell culture media). To address this issue, we developed a highly specific and accurate ELISA assay that quantifies EVs even in crude samples. With ultra-pure EV standard samples, this assay showed reliable quantitative result of EV detection to support method development as well as in-process control of large-scale EV manufacture. The detection range of this assay is from 4.1E7 to 3E10 EVs/mL, with an LOD of 1.04E7 EVs/mL and an LOQ of 3.21E7 EVs/mL. We therefore developed this assay into a testing kit and demonstrated that this EV quantification ELISA kit is capable of ensuring minimal interference from impurities and supporting the process development and in-process control in EV production.
BibTeX
@misc{zhou2024development,
  author = {Xin Zhou and Wenli Wang and Lei Zhang and Shiyi Yang and Xincheng Peng and Xin Zhang and Jinxiu Zhao and Xinjun He and Ke Xu},
  title = {{Development of an ELISA assay for EV quantification to assist the large-scale EV manufacture}},
  year = {2024},
  doi = {10.1101/2024.10.31.621446},
  howpublished = {bioRxiv},
}
Figure